Valuation: MacroGenics, Inc.

Market Cap 240M 209M 194M 178M 337M 22.94B 342M 2.29B 899M 11.42B 902M 883M 38.29B P/E 2026 *
-5.64x
P/E 2027 * -2.47x
Enterprise Value 240M 209M 194M 178M 337M 22.94B 342M 2.29B 899M 11.42B 902M 883M 38.29B EV / Sales 2026 *
1.46x
EV / Sales 2027 * 2.55x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day-2.38%
1 week-0.27%
Current month-20.13%
1 month-20.13%
3 months+17.89%
6 months+110.86%
Current year+129.19%
1 week 3.61
Extreme 3.61
4.06
1 month 3.36
Extreme 3.36
5.06
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
28.09
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
19/5/26 Free

Director

25,750 0.0405%
19/5/26 Free

Director

25,750 0.0405%
19/5/26 Free

Founder

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
-2.38%-0.27%+136.54%-22.64% 240M
+2.35%+0.77%+29.92%+85.38% 55.23B
-0.21%-6.52%+42.39%+64.10% 53.75B
-2.44%+1.40%-15.74%-16.80% 23.48B
-2.85%-7.78%-8.09%+346.36% 22B
+2.49%-1.27%+15.99%-10.53% 19.78B
+0.79%-2.39%+26.99%-31.34% 17.44B
+0.58%-7.23%+24.50%+519.07% 14.66B
-5.25%-4.23%+46.41%+169.05% 14.07B
+3.41%-7.83%+161.76%+284.91% 13.02B
Average -0.35%-2.75%+46.07%+138.75% 23.37B
Weighted average by Cap. +0.17%+0.08%+31.33%+121.20%

Financials

2026 *2027 *
Net sales 164M 143M 133M 122M 231M 15.69B 234M 1.57B 615M 7.81B 617M 604M 26.2B 94.26M 81.94M 76.27M 70.02M 132M 9B 134M 899M 353M 4.48B 354M 346M 15.02B
Net income -18.31M -15.91M -14.81M -13.6M -25.68M -1.75B -26.08M -175M -68.52M -870M -68.75M -67.24M -2.92B -127M -110M -103M -94.37M -178M -12.13B -181M -1.21B -476M -6.04B -477M -467M -20.24B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
01/08/26 US$3.690 -2.38% 410,745
30/07/26 US$3.780 +3.00% 274,227
29/07/26 US$3.670 -4.68% 414,023
28/07/26 US$3.850 -3.75% 874,968
27/07/26 US$4.000 +8.11% 666,160
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.780USD
Average target price
6.750USD
Spread / Average Target
+78.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock